Abstract 103P
Background
Microsatellite instability (MSI) is a powerful predictor for the efficacy of immune checkpoint inhibitor (ICI) therapy across tumor types. Although conventional MSI testing strategies are widely used, NGS represents a promising tool for MSI detection. We have developed and validated the NGS test system for MSI detection in solid tumors.
Methods
The following sample types were selected for validation of our test system: G1 - archive FFPE tumor samples collected from patients with known MSI status; G2 - archive paired (FFPE/ctDNA) samples collected from patients with tumors where MSI is uncommon (<1%); G3 - paired (FFPE/ctDNA) MSI+ samples. All FFPE samples were tested using the gold standard (5-loci PCR, 4-antibody IHC). Samples were considered MSI+ if PCR or IHC were positive; MSI- when both were negative. Detection of MSI was performed using k-mer distributions of 28 loci.
Results
A total of 123 samples for 109 patients were analyzed - 77 (62.6%) FFPE, 46 (37.4%) ctDNA; 6 patients had paired samples. A total of 30 (FFPE, 83% CRC), 72 (41 FFPE, 31 ctDNA; 62.3% NSCLC) and 21 (6 patients; 6 FFPE, 15 ctDNA; 66.7% CRC) were selected for G1, G2 and G3, respectively. Rate of agreement (κ) between NGS and gold standard in G1 was 0.8 (95% CI, 0.58-1) [κ for NGS/PCR 0.93 (95% CI, 0.8-1)], and 1 in G3. In G2, 100% of samples were MSS following NGS. In G3, for all 6 samples there were no disagreements between NGS and gold standard. Across all analyzed FFPE samples, κ between NGS and gold standard was 0.9 (95% CI 0.88-0.92). When comparing results of PCR and IHC (FFPE samples), low concordance was noted (κ=0.5, 95% CI, 0.22-0.78). High concordance was observed between PCR and NGS (κ=0.94, 95% CI, 0.83-1). Concordance of IHC and NGS was low (κ=0.55, 95% CI, 0.28-0.83). Sensitivity / specificity of NGS vs IHC in detecting MSI were 76.2% / 80%. Sensitivity / specificity of NGS vs PCR were 95.5% / 100%. Sensitivity / specificity of NGS in detecting MSI using ctDNA vs FFPE were 100% / 100%.
Conclusions
Low concordance was observed between IHC and PCR for MSI detection (κ=0.5, 95% CI, 0.22-0.78). Concordance of PCR and NGS was high (κ=0.94, 95% CI, 0.83-1); concordance between IHC and NGS was lower (κ=0.55, 95% CI, 0.28-0.83). Sensitivity of MSI detection using ctDNA was 100%.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
This study was supported by Russian Science Foundation (grant № 22-75-10154).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
93P - A new platform for fast-track molecular stratification of endometrial carcinomas enabling timely treatment decisions in precision oncology
Presenter: Susanne Walz
Session: Cocktail & Poster Display session
Resources:
Abstract
94P - Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC
Presenter: Frank Borm
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)
Presenter: Betzabel Cajiao Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in endometrial cancer (EC) patients
Presenter: Simona Duranti
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Prospects of liquid biopsy in determining prognosis in children with HGG and DIPG
Presenter: Olga Regentova
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Liquid biopsy in NSCLC: A promising tool to predict immunotherapy response
Presenter: Ana Fernández
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Comprehensive genomic sequencing as an ancillary diagnostic tool for pathologists
Presenter: Dan Miller
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Standard serum biomarkers to help predict a cancer diagnosis in patients with non-specific symptoms: Data from Guy´s rapid diagnostic clinic
Presenter: Maria Monroy Iglesias
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Patient-derived organoids to optimize CDK4/6 inhibitor-based treatment selection in early breast cancer
Presenter: Carla Alves
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - MicroRNAs in urine and saliva as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia
Presenter: Alejandra Pando-Caciano
Session: Cocktail & Poster Display session
Resources:
Abstract